Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer

Lung Cancer

Volumn 54, Issue 3, 2006, Pages 331-338

  Trodella, L ^a   De Marinis, F ^b   D'Angelillo, R M ^a   Ramella, S ^a   Cesario, A ^c,d   Valente, S ^e   Nelli, F ^f   Migliorino, M R ^b   Margaritora, S ^c   Corbo, G M ^e   Porziella, V ^c   Ciresa, M ^e   Cellini, F ^a   Bonassi, S ^g   Russo, P ^g   Cortesi, E ^f   Granone, P ^c  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d IRCCS SAN RAFFAELE PISANA   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

Author keywords

Chemoradiation; Concurrent radio chemotherapy; Conformal radiotherapy; Gemcitabine; Induction chemotherapy; Locally advanced disease; Non small cell lung cancer; Phase II trial

Indexed keywords

CISPLATIN; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DRUG SAFETY; ESOPHAGITIS; ESOPHAGUS DISEASE; FEASIBILITY STUDY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPNEA; HYPOXIA; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TOXICITY; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750390862     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.07.020     Document Type: Article

References (46)

1. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
2. Pfister D.G., Johnson D.H., Azzoli C.G., Sause W., Smith T.J., Baker Jr. S., et al., American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353
3. Belani C.P., Choy H., Bonomi P., Scott C., Travis P., Haluschak J., et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 23 (2005) 5883-5891
4. Vokes E.E., Herndon J.E., Kelley M.J., Watson D., Cicchetti M.G., Green M.R., et al. Induction chemotherapy followed by concomitant radio-chemotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. J Clin Oncol 22 (2004) 7005 (abstr)
5. Trodella L., Granone P., Valente S., Margaritora S., Macis G., Cesario A., et al. Neoadjuvant concurrent radio-chemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging. Ann Oncol 1 (2004) 389-398
6. Trodella L., Granone P., Valente S., Turriziani A., Macis G., Corbo G.M., et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 20 (2002) 804-810
7. De Marinis F., Nelli F., Migliorino M.R., Martelli O., Cortesi E., Treggiari S., et al. Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA (N2) nonsmall cell lung carcinoma: a Phase II multicenter study. Cancer 98 (2003) 1707-1715
8. Frasci G., Panza N., Comella P., Nicolella G.P., Natale M., Manzione L., et al. Cisplatin, GEM, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group. J Clin Oncol 17 (1999) 2316-2325
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 32 (2000) 205-216
10. American Thoracic Society: standardization of spirometry - 1987 update. Am Rev Resp Dis 1987; 136:1285-98.
11. Kaplan E.M., and Maier P. Non-parametric estimation for incomplete observations. J Am Stat Ass 53 (1958) 457-481
12. StartXact user manual. Cambridge: Cytel Software 1992; 5.21-5.26.
13. Cox D.R. Regression models and life-table. J R Stat Soc 334 (1972) 187-220
14. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 (1999) 2692-2699
15. Curran W.J., Scott C.B., Langer C.J., Komaki R., Lee J.S., Hauser S., et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 22 (2003) 2499 (abstr)
16. Huber R.M., Schmidt M., Flentje M., Poellinger B., Gosse H., Willner J., et al. Induction chemotherapy and following simultaneous radio/chemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB). Proc Am Soc Clin Oncol 22 (2003) 2501 (abstr)
17. Gandara D.R., Chansky K., Albain K.S., Leigh B.R., Gaspar L.E., Lara Jr. P.N., et al., Southwest Oncology Group. Consolidation docetaxel after concurrent radio-chemotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21 (2003) 2004-2010
18. Albain K.S., Crowley J.J., Turrisi III A.T., Gandara D.R., Farrar W.B., Clark J.I., et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 20 (2002) 3454-3460
19. Vokes E.E., Herndon II J.E., Crawford J., Leopold K.A., Perry M.C., Miller A.A., et al. Randomized phase II study of cisplatin with GEM or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant radio-chemotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20 (2002) 4191-4198
20. Bradley J.D., Ieumwananonthachai N., Purdy J.A., Wasserman T.H., Lockett M.A., Graham M.V., et al. Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 52 (2002) 49-57
21. Martel M.K., Strawderman M., Hazuka M.B., Turrisi A.T., Frass B.A., and Lichter A.S. Volume and dose parameters for survival of non-small cell lung cancer patients. Radiother Oncol 44 (1997) 23-29
22. Etiz D., Marks L.B., Zhou S.M., Bentel G.C., Clough R., Hernando M.L., et al. Influence of tumor volume on survival in patients irradiated for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 53 (2002) 835-846
23. Socinski M.A., Morris D.E., Halle J.S., Moore D.T., Hensing T.A., Limentani S.A., et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol 22 (2004) 4341-4350
24. Shewach D.S., Hahn T.M., Chang E., Hertel L.W., and Lawrence T.S. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 15 (1994) 3218-3223
25. van Putten J.W., Price A., van der Leest A.H., Gregor A., Little F.A., and Groen H.J. A Phase I study of GEM with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 9 (2003) 72-77
26. Blackstock A.W., Lesser G.J., Fletcher-Steede J., Case L.D., Tucker R.W., Russo S.M., et al. Phase I study of twice-weekly GEM and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 1281-1289
27. Emami B., Mirkovic N., Scott C., Byhardt R., Graham M.V., James Andras E., et al. The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data. Lung Cancer 41 (2003) 207-214
28. Bradley J.D., Wahab S., Lockett M.A., Perez C.A., and Purdy J.A. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys 56 (2003) 342-347
29. Rosenzweig K.E., Sim S.E., Mychalczak B., Braban L.E., Schindelheim R., and Leibel S.A. Elective nodal irradiation in the treatment of non-small-cell lung cancer with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 681-685
30. Hayman J.A., Martel M.K., Ten Haken R.K., Normolle D.P., Todd R.F.3r., Littles J.F., et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: update of a phase I trial. J Clin Oncol 19 (2001) 127-136
31. Martel M.K., Sahijdak W.M., Hayman J.A., and Bell D. Incidental dose to clinically negative nodes from conformal treatment fields for non-small cell lung cancer. Int J Radiat Oncol Biol Phys 45 (1999) S244 abstract 186
32. Armstrong J.G. Target volume definition for three-dimensional conformal radiation therapy of lung cancer. Br J Radiol 71 (1998) 587-594
33. ICRU 62. Prescribing, Recording and Reporting Photon Beam Therapy; 1999 [Supplement to ICRU Report 50].
34. Galetta D., Cesario A., Margaritora S., Porziella V., Macis G., D'Angelillo R.M., et al. Enduring challenge in the treatment of nonsmall cell lung cancer with clinical stage IIIB: results of a trimodality approach. Ann Thorac Surg 76 (2003) 1802-1808
35. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi A.T.3r., Weick J.K., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
36. Cortesi E., Trodella L., Nelli F., D'Angelillo R., Ramella S., D'Auria G., et al. Induction chemotherapy (CT) with gemcitabine (G), paclitaxel (T), and cisplatin (P) and subsequent radiotherapy (TRT) with concomitant G for stage IIIB non-small cell lung cancer (NSCLC): results of a multicenter phase II study. Proc Am Soc Clin Oncol 22 (2003) 669 (abstr 2690)
37. Pirker R. Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer. Lung Cancer 38 (2002) S53-S55
38. Arriagada R., Le Chevalier T., Quoix E., Ruffie P., de Cremoux H., Douillard J.Y., et al. ASTRO plenary: effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. Int J Radiat Oncol Biol Phys 20 (1991) 1183-1190
39. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 16 (1998) 622-634
40. Graham M.V., Purdy J.A., Emami B., Harms W., Bosch W., Lockett M.A., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
41. Hernando M.L., Marks L.B., Bentel G.C., Zhou S.M., Hollis D., Das S.K., et al. Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51 3 (2001) 650-659
42. Hirota S., Tsujino K., Endo M., Kotani J., Satouchi M., Kado T., et al. Dosimetric predictors of radiation esophagitis in patients treated for non-small-cell lung cancer with carboplatin/paclitaxel/radiotherapy. Int J Radiat Oncol Biol Phys 51 2 (2001) 291-295
43. Kelly K., Gaspar L.E., Chansky K., Albain K.S., Crowley J., and Gandara D.R. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol (2005) (abstr 7058)
44. Delbaldo C., Syz N., Michiels S., Le Chevalier T., and Pignon J.P. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature. Proc Am Soc Clin Oncol (2003) (abstr 2507)
45. Divers S.G., Spencer S.A., Carey D., Busby E.M., Hyatt M.D., and Robert F. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 6664-6673
46. Galetta D., Cesario A., Margaritora S., Porziella V., Piraino A., D'Angelillo R.M., et al. Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. J Thorac Cardiovasc Surg 131 (2006) 314-321